BR112015023332A2 - Toxóide, composições e método relacionados - Google Patents
Toxóide, composições e método relacionadosInfo
- Publication number
- BR112015023332A2 BR112015023332A2 BR112015023332A BR112015023332A BR112015023332A2 BR 112015023332 A2 BR112015023332 A2 BR 112015023332A2 BR 112015023332 A BR112015023332 A BR 112015023332A BR 112015023332 A BR112015023332 A BR 112015023332A BR 112015023332 A2 BR112015023332 A2 BR 112015023332A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- toxoid
- compositions
- inactivating
- toxoids
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
TOXÓIDE, COMPOSIÇÕES E MÉTODO RELACIONADOS. A presente invenção refere-se de forma geral ao campo da inativação de toxina. Mais especificamente, refere-se a toxinas de Clostridium, métodos de inativação destas toxinas e composições (por exemplo, vacinas) compreendendo toxóides (por exemplo, produzidos por estes métodos). São propocionados métodos de produção de um toxóide de C. difficile compreendendo inativação uma toxina de C. difficile com formaldeído. Os toxóides preparados por estes métodos são estáveis em altas temperaturas (por exemplo, 37°C) e permanece não citotóxica com formaldeído residual mínimo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361790423P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/029035 WO2014144567A2 (en) | 2013-03-15 | 2014-03-14 | Toxoid, compositions and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015023332A2 true BR112015023332A2 (pt) | 2017-08-22 |
Family
ID=50489430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015023332A BR112015023332A2 (pt) | 2013-03-15 | 2014-03-14 | Toxóide, composições e método relacionados |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20160045586A1 (pt) |
| EP (1) | EP2968507A2 (pt) |
| JP (1) | JP2016516721A (pt) |
| KR (1) | KR20150133770A (pt) |
| CN (1) | CN105338997A (pt) |
| AR (1) | AR095669A1 (pt) |
| AU (1) | AU2014228956A1 (pt) |
| BR (1) | BR112015023332A2 (pt) |
| CA (1) | CA2907154A1 (pt) |
| HK (1) | HK1213800A1 (pt) |
| SG (1) | SG11201507608PA (pt) |
| TW (1) | TWI624474B (pt) |
| WO (1) | WO2014144567A2 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2742823T3 (es) | 2011-04-22 | 2020-02-17 | Wyeth Llc | Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| AU2014277981B2 (en) | 2013-06-14 | 2019-06-20 | Sanofi Pasteur Inc. | Compositions and methods of immunizing against C. difficile |
| BR112017024443A2 (pt) * | 2015-05-15 | 2018-10-23 | Sanofi Pasteur Inc | métodos para imunização contra clostridium difficile |
| MX2019013779A (es) * | 2017-06-09 | 2020-01-13 | Hipra Scientific Slu | Vacuna que comprende toxoides de clostridium. |
| US10096313B1 (en) * | 2017-09-20 | 2018-10-09 | Bose Corporation | Parallel active noise reduction (ANR) and hear-through signal flow paths in acoustic devices |
| WO2023107842A2 (en) * | 2021-12-06 | 2023-06-15 | Rutgers, The State University Of New Jersey | Compositions and methods for treating cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6967088B1 (en) * | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
| US5610023A (en) * | 1995-03-31 | 1997-03-11 | Lee Laboratories, Inc. | Method of purification of clostridium difficile toxin A and production of mono-specific antibodies |
| EP2305293A3 (en) * | 1997-10-20 | 2013-11-06 | Sanofi Pasteur Biologics Co. | Immunization against Clostridium difficile disease |
| US6969520B2 (en) * | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| US6669520B2 (en) | 2001-09-19 | 2003-12-30 | United Microelectronics Corp. | Method of fabricating an LC panel |
| KR101540920B1 (ko) | 2007-07-26 | 2015-08-03 | 사노피 파스퇴르 리미티드 | 항원-애주번트 조성물 및 방법 |
| NO2198007T3 (pt) * | 2007-09-14 | 2018-03-24 | ||
| GB201011968D0 (en) * | 2010-07-16 | 2010-09-01 | Secr Defence | Toxoiding method |
-
2014
- 2014-03-14 SG SG11201507608PA patent/SG11201507608PA/en unknown
- 2014-03-14 US US14/776,145 patent/US20160045586A1/en not_active Abandoned
- 2014-03-14 KR KR1020157029566A patent/KR20150133770A/ko not_active Application Discontinuation
- 2014-03-14 AU AU2014228956A patent/AU2014228956A1/en not_active Abandoned
- 2014-03-14 EP EP14717950.1A patent/EP2968507A2/en not_active Withdrawn
- 2014-03-14 CA CA2907154A patent/CA2907154A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/029035 patent/WO2014144567A2/en active Application Filing
- 2014-03-14 CN CN201480021368.4A patent/CN105338997A/zh active Pending
- 2014-03-14 JP JP2016502966A patent/JP2016516721A/ja active Pending
- 2014-03-14 BR BR112015023332A patent/BR112015023332A2/pt not_active IP Right Cessation
- 2014-03-17 TW TW103110044A patent/TWI624474B/zh not_active IP Right Cessation
- 2014-03-18 AR ARP140101275A patent/AR095669A1/es unknown
-
2016
- 2016-02-18 HK HK16101854.5A patent/HK1213800A1/zh unknown
-
2017
- 2017-10-02 US US15/722,029 patent/US20180028637A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016516721A (ja) | 2016-06-09 |
| SG11201507608PA (en) | 2015-10-29 |
| AR095669A1 (es) | 2015-11-04 |
| CN105338997A (zh) | 2016-02-17 |
| AU2014228956A1 (en) | 2015-10-08 |
| EP2968507A2 (en) | 2016-01-20 |
| TW201514197A (zh) | 2015-04-16 |
| KR20150133770A (ko) | 2015-11-30 |
| CA2907154A1 (en) | 2014-09-18 |
| WO2014144567A3 (en) | 2014-12-04 |
| US20180028637A1 (en) | 2018-02-01 |
| HK1213800A1 (zh) | 2016-07-15 |
| WO2014144567A2 (en) | 2014-09-18 |
| TWI624474B (zh) | 2018-05-21 |
| US20160045586A1 (en) | 2016-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015023332A2 (pt) | Toxóide, composições e método relacionados | |
| BR112016012870A2 (pt) | ?métodos e composições para melhorar a produção de alface | |
| SG10201808151RA (en) | Cortistatin analogues and syntheses and uses thereof | |
| CA2902795C (en) | Glycopyrrolate salts | |
| MX2017004617A (es) | Variantes estabilizadas de alfa amilasa y su uso. | |
| MX349119B (es) | Vacuna de virus de dengue inactivado. | |
| CO2020001927A2 (es) | Método de producción de composiciones farmacéuticas que comprende el virus chikungunya inmunogénico chikv-delta5nsp3 | |
| BR112015031913A2 (pt) | processo para a fabricação de amino-benzoxazinonas 4-propargilatadas e sua utilização | |
| NZ738538A (en) | 6-amino-quinoline-3-carbonitrils as cot modulators | |
| BR112017008176A2 (pt) | método de preparação do carbonato de ácido glicérico. | |
| MX2015008766A (es) | Compuestos cbd fluorados, composiciones y usos de los mismos. | |
| MX2015010305A (es) | Vacuna de combinacion para virus sincitial respiratorio e influenza. | |
| PH12015501888A1 (en) | Novel bacteriophage and antibacterial composition comprising the same | |
| MX2015000748A (es) | Metodo para la degradacion de queratina y uso del hidrolizado de queratina producido. | |
| BR112013025424A2 (pt) | processos para produzir uma composição imunogênica, e para fabricar uma vacina, e, composição imunogênica | |
| PH12018502120A1 (en) | Live attenuated alphavirus constructs and methods and uses thereof | |
| AU2018253594A1 (en) | Dihydroxyphenyl neurotransmitter compounds, compositions and methods | |
| UA116697C2 (uk) | Композиція для запобігання зараженню видами роду mycoplasma | |
| BR102014009838B8 (pt) | Método para produzir um l-aminoácido | |
| BR112017023969A2 (pt) | ?microrganismo do gênero escherichia que produz l-triptofano e um método para produzir l- triptofano com o uso do mesmo? | |
| BR112017000022A2 (pt) | nanoparticulas terapêuticas direcionadas a alvo e métodos de produção e uso dessas partículas | |
| BR112014029264A2 (pt) | microcápsulas contendo um oxidável ativa, e um processo para a preparação do mesmo | |
| PH12015502115A1 (en) | Compositions and methods for live, attenuated alphavirus formulations | |
| MY174818A (en) | Immunogenic compostion comprising mycoplasma antigens | |
| BR112018075794A2 (pt) | produção de neurotoxinas clostridiais ativadas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2557 DE 07/01/2020. |